A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
Status:
Completed
Trial end date:
2019-12-20
Target enrollment:
Participant gender:
Summary
Chronic hypoparathyroidism is a life-long and irreversible disease for which the chronic
administration of rhPTH(1-84) is a potential treatment option. The group of participants in
the AAAE0544 core study has been taking rhPTH(1-84) for the treatment of hypoparathyroidism
for up to 11 years. This study is designed to extend this experience and gain knowledge about
how safe and effective rhPTH(1-84) is in participants with hypoparathyroidism over a
long-term duration.